Publications

Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Mascunano RC, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Cardio-oncology (London, England). 2026. PMID: 42432812

Kamran SC, Borges M, Michalski J, Lee WR, Sandler HM, Crook J, Pollack A, Hurwitz MD, Valicenti RK, Bruner DW, Lukka H, Jones CU, Roach M, Lawton C, Rosenthal SA, Pisansky TM, Spratt D, Vapiwala N, Efstathiou J, Miyamoto D, Mouw K, Vyfhuis M, Le QT, Willers H, Van Allen E, Huang F, Bahary JP, Helou J, Pugh SL, Wenzel J, Tran P. Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology. JCO precision oncology. 2026. PMID: 42418740

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan X, Bamias A. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treat ESMO open. 2026. PMID: 42418909

Hart L, Rugo HS, Sharma P, Sammons S, Gadi VK, Mavros P, Kaur M, Boualam N, Keane C, Sopher G, Pathak P, Tarantino P. Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer ESMO open. 2026. PMID: 42413325

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E, PRISM-AML Investigators. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 42391582

Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. American journal of hematology. 2026. PMID: 42393840

Vogel A, Kelley RK. Systemic therapy for HCC: Doublets, triplets and beyond. Journal of hepatology. 2026. PMID: 42744526

Schroers-Martin JG, Merryman R, Spinner MA, Yeung A, Chang C, Silin C, Powell M, Armand P, Shipp M, Advani R. Anti-CD47 antibody magrolimab with pembrolizumab in patients with relapsed / refractory classic Hodgkin lymphoma. Haematologica. 2026. PMID: 42389806

Piawah S, Lin OM, Mendiola DM, Yom SS, Macaire G, Cheng SW, Atreya CE. Integrative Oncology Approaches for Gastrointestinal Symptoms and Risk Reduction in Patients With Digestive Tract Cancers. Seminars in radiation oncology. 2026. PMID: 42288373

Hotca AE, Lin OM, Piawah S, Mendiola DM, Yom SS, Kuon C, Atreya CE. The Role of the Microbiome and Gut Health in Patients With Digestive Tract Cancers. Seminars in radiation oncology. 2026. PMID: 42288363

Roddie C, Day W, Raymond M, Cluxton D, Caulfield J, Dainton-Smith H, McElwee B, Hu Y, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Yallop D, Barba P, Guerreiro M, Yared JA, Hodby K, Shah BD, Brugger W, Lao-Sirieix P, Bishop MR, DeAngelo DJ, Jabbour E, Park JH. CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study. Cancer Research Communications. 2026. PMID: 42241689

Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Leitch AM, Lyons J, McCloskey S, McShane M, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria CA, Schneider BP, Smith ML, Soliman H, Speers C, Telli ML, Wei M, Wisinski KB, Yellala A, Yeung KT, Young JS, Schonfeld R, Kumar R. Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 42425164

Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Cordoba Mascunano R, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026. PMID: 42377594

Wang Y, Quinones C, Kang I, Rugo H, Martinez E, Seewaldt V, Mortimer J, Nath A, Jones V. Multi-state modeling associates proliferation genes with early estrogen receptor-positive breast cancer recurrence and survival. Research square. 2026. PMID: 42427829

Epstein L, Weiner AC, Verma A, Saeidi M, Carnevale J, Marson A, Engelhardt BE. Segmentation-free analysis of live-cell imaging data reveals how T cell modifications influence cancer cell aggregation dynamics. Scientific Reports. 2026. PMID: 42380368

Silverstein JF, Huppert LA, Schwede M, Goglin S, Johnson TP, Babik JM, Brondfield S. Optimizing a Hematology/Oncology Curriculum for Internal Medicine Residents: A Two-Institution Modified Delphi Study. Journal of cancer education : the official journal of the American Association for Cancer Education. 2026. PMID: 42380386

Reyes KR, Zhu R, Herberts C, Dutta P, Wray A, Mitchell B, Balkhi SS, Zhu X, Chu CE, Porten SP, Friedlander TW, Chou J, Seyedin SN, Sharma S, Malhotra M, ElNaggar AC, Liu MC, Ayanambakkam A, Koshkin VS. Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab. European urology oncology. 2026. PMID: 42379901

Jones V, Wang Y, Quinones C, Aljaber D, Nelson E, Nath A, Kang I, Rugo H, Yee L, Seewaldt V, Mortimer J. Baseline gene expression and dynamic endocrine therapy use in ER+ breast cancer: associations with recurrence in a real-world cohort. Research square. 2026. PMID: 42427842

Faramand RG, Zhang A, Roloff GW, Aldoss I, Advani AS, Battiwalla M, Boccucci J, Byrd K, Cassaday RD, Connor M, Dykes KC, Hilal T, Kopmar NE, Kota VK, Lee CJ, Leonard JT, Lill GR, Lin C, Logan AC, Majhail NS, Malik SA, McCauley R, Moore J, Mountjoy L, O'Connor T, O'Dwyer KM, Bobillo SO, Oliai CH, Othman T, Ramakrishnan A, Sandhu K, Schwartz M, Shaughnessy P, Srinagesh HK, Sutherland KC, Tan V, Tsai SB, Ulrickson M, Wang ES, Yaghmour G, Frey NV, Shah BD, Muffly LS. Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblasti Transplantation and cellular therapy. 2026. PMID: 42364734

Rugo HS, Cescon DW, Schmid P, Nowecki Z, Im SA, Md Yusof M, Gallardo C, Iwata H, Lipatov O, Cruz F, Barrios CH, Hegg R, Loi S, Gion M, Otero MT, Árkosy P, Tarnawski R, Yao L, Mejia J, Pan W, Cortés J. Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events. NPJ breast cancer. 2026. PMID: 42362563